|

Autologous CD5 CAR T-cells Clinical Trials

2 actively recruiting trials

Pipeline

Phase 1/2: 2

Top Sponsors

  • Beijing GoBroad Hospital2

Indications

  • T-cell Malignancies2
  • T-Cell Acute Lymphocytic Leukemia2
  • Refractory Acute Lymphoblastic Leukemia2
  • Acute Lymphoblastic Leukemia, in Relapse2
  • Cancer2

Other2 trials

A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
Phase 1/2
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.